The Brazil Contract Development and Manufacturing Organization (CDMO) Market reached a valuation of approximately USD 10.64 Billion in 2025 and is projected to expand at a strong CAGR of 8.80% during the forecast period of 2026 to 2035, ultimately reaching an estimated value of around USD 24.73 Billion by 2035. This significant growth is being driven by Brazil’s well-established pharmaceutical manufacturing base, increasing outsourcing of drug development and production, rising demand for biologics and biosimilars, regulatory alignment with global standards, and expanding investments in advanced biopharmaceutical capabilities.

What Is a CDMO?

A Contract Development and Manufacturing Organization (CDMO) provides end-to-end services to pharmaceutical and biotechnology companies, including drug development, formulation, clinical trial support, and large-scale commercial manufacturing. CDMOs enable companies to outsource complex processes, reduce costs, and accelerate time-to-market. In Brazil, CDMOs play a critical role in supporting both domestic and international pharmaceutical companies by offering scalable manufacturing solutions, regulatory expertise, and advanced production capabilities tailored to local and global standards.

Why Is the Brazil CDMO Market Growing?

The Brazil CDMO market is being driven by increasing pharmaceutical R&D outsourcing and the growing need for cost-efficient drug development solutions. As pharmaceutical companies focus more on innovation and core competencies, they are increasingly relying on CDMOs for manufacturing and development services. Additionally, Brazil’s strong regulatory framework and improving healthcare infrastructure are enhancing its attractiveness as a regional hub for CDMO services. Rising investments in biologics, biosimilars, and advanced therapies are further accelerating market expansion.

Request a Free Sample Report

https://www.expertmarketresearch.com/reports/brazil-contract-development-and-manufacturing-organization-cdmo-market/requestsample

Recent Industry Developments and Updates in 2024, 2025 and 2026

The Brazil CDMO industry has been witnessing steady advancements driven by increasing investments and regulatory improvements. Brazil’s regulatory authority is strengthening alignment with international standards, improving the country’s position for global pharmaceutical collaborations. Additionally, growing investments in biologics and gene therapies are enhancing CDMO capabilities, while infrastructure development and technology adoption are enabling more efficient and scalable manufacturing solutions. These developments highlight Brazil’s emergence as a strategic CDMO hub in Latin America.

Key Drivers Fueling the Brazil CDMO Market Growth

Several factors are accelerating market growth across Brazil, including rising demand for biologics and biosimilars, increasing outsourcing of pharmaceutical manufacturing, strong regulatory support and international alignment, expansion of pharmaceutical R&D activities, and continuous improvements in manufacturing infrastructure and skilled workforce availability.

Is CDMO Important in the Pharmaceutical Industry?

Yes, CDMOs are essential for the pharmaceutical and biotechnology industries as they enable companies to streamline operations, reduce capital expenditure, and accelerate drug development timelines. In Brazil, CDMOs are particularly important in supporting innovation, improving access to advanced therapies, and enhancing local manufacturing capabilities. They also help companies navigate regulatory complexities while ensuring compliance with international quality standards.

Emerging Trends Shaping the Brazil CDMO Industry

The market is witnessing several transformative trends, including increasing focus on biologics and biosimilars manufacturing, rising adoption of advanced technologies such as cell and gene therapy production, expansion of end-to-end CDMO services, growing international collaborations, and strengthening of Brazil’s position as a regional pharmaceutical manufacturing hub.

Brazil CDMO Market Segmentation

The Brazil CDMO market is comprehensively segmented to provide detailed insights into growth opportunities.

Breakup by Service Type

Contract Manufacturing Organization and Contract Research Organization. Contract manufacturing services dominate the market due to their scalability and cost-efficiency, while contract research services are gaining traction with increasing R&D outsourcing.

Breakup by Therapeutic Area

Oncological diseases, metabolic disorders, neurological disorders, respiratory diseases, cardiovascular diseases, infectious diseases, and others. Oncology leads the market due to the high demand for cancer therapeutics and biologics development.

Breakup by End User

Pharmaceutical and biopharmaceutical companies, medical device companies, and others. Pharmaceutical and biopharmaceutical companies dominate the market as primary users of CDMO services.

Which Segment Leads the Brazil CDMO Market?

Oncology is the leading therapeutic segment in the Brazil CDMO market due to increasing cancer prevalence and growing demand for advanced biologic treatments. Additionally, contract manufacturing services dominate due to their critical role in large-scale drug production, while pharmaceutical and biopharmaceutical companies remain the largest end users driving demand.

Competitive Landscape: Leading Brazil CDMO Companies

The Brazil CDMO market includes a mix of global and regional pharmaceutical manufacturing and development companies focusing on innovation, scalability, and strategic partnerships. Major companies operating in the market include Laboratorio Cristalia, Recipharm AB, Boehringer Ingelheim, Patheon Pharma Services (Thermo Fisher Scientific Inc.), Pfizer Inc., AVANTI PESQUISA CLINICA LTD, Lonza Group, Ache Laboratorios Farmaceuticos S.A., WuXi AppTec, Bionovis S.A., Eurofarma Laboratorios S.A., AGC Pharma Chemicals Inc., B. Braun SE, and WuXi Biologics.

Frequently Asked Questions (FAQs)

Q1. What was the Brazil CDMO market size in 2025?

The market reached approximately USD 10.64 Billion in 2025. 

Q2. What is the projected CAGR of the Brazil CDMO market between 2026 and 2035?

The market is expected to grow at a CAGR of 8.80% during the forecast period.

Q3. What will the Brazil CDMO market be worth by 2035?

The market is projected to reach around USD 24.73 Billion by 2035. 

Q4. What are the major drivers of the Brazil CDMO market?

Key drivers include increasing R&D outsourcing, demand for biologics, regulatory improvements, and infrastructure development.

Q5. Which segment leads the Brazil CDMO market?

Oncology leads among therapeutic areas, while contract manufacturing dominates by service type.

Q6. What are the key trends in the Brazil CDMO market?

Major trends include biologics expansion, advanced therapy manufacturing, and global collaborations.

Q7. Who are the key players in the Brazil CDMO market?

Leading players include Thermo Fisher Scientific (Patheon), Lonza, Pfizer, Recipharm, and WuXi Biologics.